SetPFPGroupVar.htm
   
SetPProProdListVar.htm

New User? Register Now

Returning User? Sign In

Benefits of registering


login.htm

Visit other Pfizer sites
Search Medical Responses
View an extensive list of Pfizer sites
ppn-vr-sso-links.htm

Share Your Feedback
Product Centers | CAMPTOSAR® (irinotecan hydrochloride injection)
 
1st-line bevacizumab | 1st-line FOLFIRI | FOLFIRI/FOLFOX | 2nd-and-later-line
CAMPTOSAR(R) (irinotecan hydrochloride injection) Indication Statement CAMPTOSAR Injection is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum.

CAMPTOSAR-based regimen + bevacizumab: safety and tolerability in 1st-line

Adverse events information relates to a phase 3, randomized, placebo-controlled, clinical trial (Hurwitz et al)1 of CAMPTOSAR + bolus 5-FU/LV + bevacizumab as 1st-line treatment of patients with metastatic carcinoma of the colon or rectum. CAMPTOSAR + bolus 5-FU/LV + bevacizumab was compared with CAMPTOSAR + bolus 5-FU/LV alone and with bolus 5-FU/LV + bevacizumab. Primary end point was OS. Secondary end points were progression-free survival (PFS), response rate, duration of response, safety, and quality of life.

Table showing percent of patients experiencing grade 3/4 adverse events for CAMPTOSAR + 5-FU/LV + bevacizumab vs CAMPTOSAR + 5-FU/LV

Most common (>5%) grade 3/4 adverse events in either treatment arm are listed.

View efficacy information related to this safety information.

Reference: 1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342. 2. Avastin [package insert]. South San Francisco, Calif: Genentech, Inc; 2006.